Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
3.360
+0.070 (2.13%)
At close: Oct 6, 2025, 4:00 PM EDT
3.470
+0.110 (3.27%)
After-hours: Oct 6, 2025, 5:30 PM EDT
Sight Sciences Revenue
Sight Sciences had revenue of $19.56M in the quarter ending June 30, 2025, a decrease of -8.45%. This brings the company's revenue in the last twelve months to $76.30M, down -3.89% year-over-year. In the year 2024, Sight Sciences had annual revenue of $79.87M, down -1.47%.
Revenue (ttm)
$76.30M
Revenue Growth
-3.89%
P/S Ratio
2.25
Revenue / Employee
$353,255
Employees
216
Market Cap
175.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 79.87M | -1.19M | -1.47% |
Dec 31, 2023 | 81.06M | 9.73M | 13.63% |
Dec 31, 2022 | 71.33M | 22.38M | 45.70% |
Dec 31, 2021 | 48.96M | 21.32M | 77.12% |
Dec 31, 2020 | 27.64M | 4.29M | 18.38% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SGHT News
- 19 days ago - Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use - GlobeNewsWire
- 26 days ago - Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 27 days ago - Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments - GlobeNewsWire
- 4 weeks ago - Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO - GlobeNewsWire
- 5 weeks ago - Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewsWire
- 2 months ago - Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease - GlobeNewsWire